Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”

Bibliographic Details
Title:	Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”
Authors:	Tournilhac, Olivier ^, Hacini, Maya ^, Bouabdallah, Kamal ^, Laribi, Kamel ^, Maerevoet, Marie ^, Ysebaert, Loic ^, Guidez, Stephanie ^, Le Gouill, Steven, André, Marc ^, Dupuis, Jehan ^, Thieblemont, Catherine, Bachy, Emmanuel ^, Daguindau, Nicolas ^, Morschhauser, Franck ^, Tricot, Sabine ^, Feugier, Pierre ^, Banos, Anne ^, Lamy De La Chapelle, Thierry ^, Chauchet, Adrien ^, Gyan, Emmanuel, Cartron, Guillaume ^, Farhat, Hassan ^, Camus, Vincent ^, Drenou, Bernard ^, Zerazhi, Hacene ^, Sibon, David ^, Nicolas-Virelizier, Emmanuelle ^, Delette, Caroline ^, Snauwaert, Sylvia ^, Straetmans, Nicole, Delarue, Richard, Parrens, Marie ^, Bossard, Céline ^, De Leval, Laurence, Gaulard, Philippe ^*, Damaj, Gandhi Laurent
Source:	In Blood 5 November 2020 136 Supplement 1:15-16
Database:	ScienceDirect